EFL020 - Zoledronate to Maintain BMD Gains After Denosumab

Join host Chase Hendrickson, MD, from Vanderbilt Unviersity Medical Center, as he talks with Amal Shibli-Rahhal, MD, from University of Iowa and John Bilezikian, MD, PhD(hon), from Columbia University Medical Center. The article featured this month is from the May 2021 issue of The Journal of Clinical Endocrinology & Metabolism: “The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After its Discontinuation.” For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/journals/endocrine-feedback-loop-podcast-series